Can I Take Calcium with Jardiance (Empagliflozin)?

Empagliflozin (brand name Jardiance, an oral SGLT2 inhibitor) does not have a known pharmacokinetic interaction with calcium supplements, and calcium is not listed as an interacting substance on the current FDA prescribing information. That is the narrow, well-supported answer. It is not, however, the whole clinical picture: people prescribed Jardiance are often also on levothyroxine, a bisphosphonate, or a thiazide diuretic, and calcium genuinely does interact with those drugs. The useful question for this page is not "does calcium interact with Jardiance" but "what in this patient's full regimen actually needs timing attention."

What is actually established

Empagliflozin works by blocking the sodium-glucose cotransporter 2 (SGLT2) in the kidney's proximal tubule, which increases urinary glucose excretion and lowers blood glucose independent of insulin. It is metabolized mainly by UDP-glucuronosyltransferase enzymes (UGT1A3, UGT1A8, UGT1A9), not by the cytochrome P450 system. Calcium is absorbed in the small intestine through pathways (active transcellular transport and passive paracellular diffusion) that do not overlap with the renal SGLT2 transporter or with UGT metabolism. There is no shared mechanism by which one substance would be expected to change the absorption or clearance of the other.

The current FDA-approved prescribing information for Jardiance lists interactions with UGT inducers/inhibitors, insulin and insulin secretagogues (additive hypoglycemia risk), and diuretics (volume depletion risk). Calcium does not appear in that list. This absence is a reasonable basis for saying no interaction has been identified in the sponsor's own interaction review, though absence from a label is not the same as a dedicated interaction trial having been conducted and published; no such trial appears in the literature reviewed for this page.

Why this combination comes up so often

Type 2 diabetes and chronic kidney disease both affect bone and mineral metabolism, and Jardiance is approved for type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. Patients in these categories, especially postmenopausal women, are frequently advised to take calcium for bone health. The overlap is about population, not about a drug-drug mechanism.

The NIH Office of Dietary Supplements recommends 1,000 mg/day of elemental calcium for most adults aged 19-50, rising to 1,200 mg/day for women over 51 and adults over 70 (NIH ODS calcium fact sheet). Jardiance use does not change these population targets. The more useful clinical step, before deciding on a supplement dose, is estimating actual dietary calcium intake, since many adults already get 600-800 mg/day from food and only need a smaller supplement to close the gap.

Where the evidence is plausible but not settled

A few mechanistic questions are reasonable to raise but are not backed by trials designed to answer them directly:

• SGLT2 inhibition and urinary calcium handling. Increased distal sodium delivery under SGLT2 blockade could plausibly alter calcium reabsorption through the sodium-calcium exchanger. Some small studies have reported modest changes in urinary calcium excretion with SGLT2 inhibitors, but this has not been confirmed in trials large enough to establish a clinical effect, and it should not be treated as a reason to change calcium dosing.
• Class-wide bone effects. Canagliflozin (a different SGLT2 inhibitor) has been associated with an increased fracture rate in at least one large outcomes trial, while empagliflozin substudies looking at bone mineral density over roughly a year did not show the same signal. Whether this difference is a true drug-specific effect, a trial-specific finding, or a chance result across the class is not fully resolved, and long-term bone density data on empagliflozin specifically remain limited.
• Calcium supplementation and cardiovascular risk. Some meta-analyses have raised a possible association between calcium supplements taken without vitamin D and a modest increase in cardiovascular events, a finding that has been disputed in later analyses adjusting for dietary calcium. Given that many Jardiance patients already carry cardiovascular or renal risk, this unresolved debate is a reasonable argument for favoring dietary calcium over high-dose supplements when either would meet the target intake, but it is not established well enough to justify telling a specific patient to avoid supplements. If this factors into an individual treatment decision, the underlying meta-analyses should be checked directly rather than taken on secondhand summary.

What is not established

There is no published pharmacokinetic interaction trial of calcium and empagliflozin specifically, positive or negative. There is no established empagliflozin-specific effect on serum calcium in patients with normal kidney function. Claims that appear in some consumer summaries about precise percentage changes in absorption, or about specific numeric fracture-risk differences between empagliflozin and other SGLT2 inhibitors, should be treated as unverified until checked against the primary trial publications; this page does not reproduce those numbers because they could not be confirmed against a specific source during this review.

The interactions that actually require timing decisions

The more consequential interactions in a typical Jardiance-plus-calcium regimen are not with Jardiance at all.

Levothyroxine. Calcium carbonate is well documented to reduce levothyroxine absorption when the two are taken together. The standard clinical practice, reflected in levothyroxine prescribing information generally, is to separate calcium and levothyroxine by at least four hours. This is unrelated to Jardiance and applies regardless of which SGLT2 inhibitor, if any, a patient takes.

Bisphosphonates. Alendronate, risedronate, and similar drugs require an empty stomach and plain water only, with food, drinks, and supplements including calcium delayed for at least 30 to 60 minutes depending on the specific agent's label. Empagliflozin has no such requirement and can be taken with food.

Thiazide diuretics. Hydrochlorothiazide and chlorthalidone reduce renal calcium excretion and can raise serum calcium. Patients taking a thiazide, Jardiance, and a calcium supplement together carry a modestly higher theoretical risk of hypercalcemia than any one of those alone, which is a reasonable basis for periodic serum calcium checks rather than for avoiding any of the three drugs.

A practical morning sequence

For a patient on empagliflozin, levothyroxine, and twice-daily calcium carbonate, one workable sequence is:

Calcium citrate does not require stomach acid and is a reasonable alternative for patients on acid-suppressing medication or with reduced stomach acid, but the choice between citrate and carbonate does not change anything about empagliflozin timing.

Evidence-status interaction assessment

Monitoring worth discussing with a prescriber

For a patient taking Jardiance and a calcium supplement long-term, reasonable topics to raise at a follow-up visit include kidney function (eGFR, already tracked for Jardiance dosing), serum calcium and albumin, phosphorus and parathyroid hormone if eGFR is reduced, and vitamin D status if the calcium is being taken for bone health. Symptoms such as nausea, constipation, confusion, or unusual fatigue can indicate hypercalcemia and warrant contacting a prescriber; muscle cramps or tingling can indicate the opposite, particularly in kidney disease patients on active vitamin D analogs.

Special situations

Postmenopausal women are the group most likely to be advised to take 1,200 mg/day of calcium and are also common Jardiance users. Nothing about being on Jardiance changes the standard NIH target, but many women already meet part of that target through diet and may only need a smaller supplement.

Heart failure patients on Jardiance often have fluid and electrolyte management as an active part of their care. This is a reasonable group in which to favor the lowest effective calcium dose and to discuss supplementation with the cardiology or heart failure team rather than self-adjusting.

Chronic kidney disease patients, particularly with eGFR below 45 mL/min/1.73m², have altered calcium and vitamin D handling. Calcium dosing in this group should be individualized based on lab values rather than following standard population recommendations, and any active vitamin D analog (such as calcitriol) should be managed by a nephrology team rather than added independently.

Patients with a history of kidney stones should generally take calcium with meals rather than between meals, since dietary-timed calcium binds oxalate in the gut and tends to reduce stone risk, while calcium taken away from meals does not have this effect. This guidance comes from general urologic nutrition principles and should be discussed with a urologist or nephrologist for an individual stone history.

Specific figures such as trial sample sizes and hazard ratios are not included here, as reported figures vary between studies and have not been independently confirmed here. Readers should consult the primary trial publications for precise numeric outcomes.